Drugs / AVT05
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05632211 | Dec 2022 → Oct 2023 | — | Alvotech Swiss AG | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05842213 | Mar 2023 → Mar 2024 | rheumatoid arthritis | Alvotech Swiss AG | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-01-27 | Teva Branded Pharmaceutical Products R&D, Inc. | Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab) tevapharm.com ↗ |
| 2025-01-27 | Teva Branded Pharmaceutical Products R&D, Inc. | Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab) tevapharm.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVT05 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05842213 ↗ |
| Modality | Monoclonal antibody | “AVT05, a recombinant, human, immunoglobulin G1қ monoclonal antibody” PMID 41212475 ↗ Nov 2025 |
| Route | Subcutaneous | “Participants received a single 50 mg/0.5 mL subcutaneous injection on Day 1” PMID 41212475 ↗ Nov 2025 |